Unlocking the promise of cell therapy via the optimized immune cell engager platform
Acepodia has designed enhanced cell therapy approaches that are differentiated with bolstered potency for enhanced tumor-killing. The company's next-generation therapies are based on proprietary immune cells combined with both novel and well-established targeting mechanisms through Antibody-Cell Conjugation (ACC) technology.
ACC binds tumor-targeting antibodies to a variety of different immune effector receptors, enhancing the lock between effector and target cells which allows for better recognition and, ultimately, killing of tumor cells. Acepodia is applying this technology to its gamma delta2 T cells and oNK cells.
γδ2 T cells are an off-the-shelf cell line that are equipped with two independent recognition pathways to sense stressed and transformed cells (e.g., TCRs as well as activating NK receptors).
oNK cells are a unique off-the-shelf natural killer cell line, with potent anticancer activity, ideally suited for application of tumor-targeting machinery, such as through ACC technology.